Matinas BioPharma shareholders approve reverse stock split and reelect directors

Matinas BioPharma Holdings, Inc.

All 7 director nominees elected; Eric Ende received 57.9M for, 10.1M withheld; 59.1M broker non-votes.
Say-on-pay proposal approved: 53.3M for, 12.0M against, 2.7M abstain.
Ratification of EisnerAmper as auditor passed: 121.9M for, 3.1M against, 2.1M abstain.
Amendment to effect reverse stock split (1:2 to 1:50) and reduce authorized shares to 250M approved: 93.0M for, 31.1M against.
Total shares represented at meeting: 127.1M, or 58.5% of outstanding common stock.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Matinas BioPharma Holdings, Inc. shareholders approved Amendment to Certificate of Incorporation to effect a reverse stock split at a ratio in the range of 1-for-2 to 1-for-50 and reduce authorized common shares to 250,000,000 at the 2023-11-01 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2023-11-01

Exact text from the filing

Our stockholders approved an amendment to our Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio in the range of 1-for-2 to 1-for-50, with such reverse stock split to be effected at such ratio, time and date, if at all, as determined by our Board of Directors in its sole discretion, and simultaneously with the reverse stock split, reduce the total number of authorized shares of common stock to 250,000,000.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Matinas BioPharma Holdings, Inc. shareholders approved Election of seven directors to serve until the 2024 annual meeting at the 2023-11-01 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-11-01

Exact text from the filing

Our stockholders elected the following individuals to serve on our board of directors until the annual meeting of shareholders to be held in 2024.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Matinas BioPharma Holdings, Inc. shareholders approved Advisory approval of the compensation of the named executive officers at the 2023-11-01 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-11-01

Exact text from the filing

Our stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Matinas BioPharma Holdings, Inc. shareholders approved Ratification of the appointment of EisnerAmper LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-11-01 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-11-01

Exact text from the filing

Our stockholders approved the ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.

View on SEC.gov

47 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Matinas BioPharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-039180

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.